Recruitment Fraud Alert
Takeda has received reports that there are instances of identity thieves posing as Takeda employees in an attempt to steal personal information from job seekers. In these cases, identity thieves visit job-related websites and invite candidates to online chats. During the chat, they press job seekers to provide bank account information and personal identification numbers. If you receive unexpected offers of employment from people claiming to work for Takeda, we suggest you do not correspond with them, do not click any hyperlinks and do not open any attachments.
At Takeda, we will never ask for personal financial information during any step of the interview nor do we charge job seekers fees as part of the recruitment process. Takeda’s recruiting correspondence will be sent by a recruiting representative with an @takeda.com email address – not @gmail.com, @yahoo.com, @hotmail.com or any other email domain service.
If you believe you have been contacted by an unauthorized person, please contact your local law enforcement agency immediately.
Translating Science Into Highly Innovative, Life-changing Medicines
For over 200 years, Takeda has focused on bringing better health and a brighter future to people around the world by translating science into life-changing medicines. Today, we are a top 10 global biopharmaceutical innovator powered by more than 5,000 people who come to work every day asking themselves the same question: How can we do more for patients?
At Takeda R&D, we do more for patients by translating science into highly innovative, life-changing medicines across our core Therapeutic Areas in Innovative Biopharma: Oncology, Rare Genetics and Hematology, Neuroscience and Gastroenterology. We have a singular focus on diseases affecting patient groups with the most urgent needs and for whom treatments do not exist or are not good enough.
INNOVATIVE BIOPHARMA FOCUS AREAS
- Rare Genetics and Hematology
Strategic Investment Areas
- Plasma-Derived Therapies
We are investing in platform capabilities in cell therapy, gene therapy and data sciences, as well as collaborating with academia and emerging biotech companies to tackle some of the most challenging problems in drug discovery and development. We are committed to our people and their growth and development. We know they are our most valuable asset and the driving force behind the innovation we strive to advance for patients.
There has never been a more exciting time to be part of Takeda R&D as we work to deliver breakthroughs to patients. We hope you will join us.
In the near- and medium- term, we anticipate delivering 11 new molecular entities with the potential for 15 launches.
new molecular entity
clinical stage assets
pipeline with orphan
- Cell & gene
- Peptides &
We seek innovation and partner to nurture it, wherever it resides.Since FY16
- 200+ active partnerships
Takeda’s commitment to transparency reflects our strong support for sharing clinical trial information to benefit patients and to foster scientific discovery in a way that maintains patient privacy and preserves the integrity of our research. Learn more at ClinicalTrials.Takeda.com.Our COVID-19 response
During the pandemic, we have focused on protecting our employees, maintaining our supply chain of medicines and therapies, reducing transmission, and supporting effected communities. We are working with other leading pharmaceutical companies focused on finding treatments through shared expertise, data, and evaluation of drug candidates. Learn more at Takeda.com.
We are focused on therapies with transformative and curative potential, which is why we’re investing in the power of innate immunity and the promise of cell therapy.
- Boston, Massachusetts, USA
- San Diego, California, USA
- Zurich, Switzerland
- Vienna, Austria
- Shanghai, China
- Shonan, Japan
- Osaka, Japan